Orchid Pharma

• 

  This Stock Has Surged 7,700% In Seven Months; How Will The Rally Pan Out?

  Orchid Pharma: New owners have to divest part of their stake of about 98 per cent in the firm, which re-listed in Mumbai in early November after emerging from bankruptcy

• 

  Orchid Pharma Jumps Over 13% On Positive Inspection Report

  USFDA releases a copy of the EIR to the establishment that was the subject of an FDA or FDA-contracted inspection when the agency determines the inspection to be closed.

• 

  Orchid Gets Final Nod from USFDA for Parkinson's Drug

  Chennai-based Orchid Pharma has received final approval from the US health regulator for its generic version of rasagiline tablets used in the treatment of Parkinson's disease.

• 

  Orchid Pharma Gets Inspection Closure Report From US Regulator

  Orchid Pharma has received an establishment inspection report (EIR) from the US Food and Drug Administration (FDA) on the successful inspection closure for its Irungattukottai formulations plant in Tamil Nadu.

• 

  Orchid Pharma Gets $800 Million Loan, Shares Gain

  Orchid Pharma gained as much as 4.70 per cent on Wednesday following the annoucement about a $800 million loan, that the drugmaker said will be used for "new growth opportunities".

• 

  Orchid Chemicals Gets US Drug Regulator's Nod for Anti-Bacterial Tablets

  The approval is with 180 days of generic drug exclusivity, it added.

• Orchid Chemicals Gets USFDA Nod for Two Generic Drugs

  Drug firm Orchid Chemicals & Pharmaceuticals has received the US health regulator's nod for generic Rivastigmine capsules and Felodipine extended release tablets aimed at treating mild to moderate dementia and hypertension, respectively.

• Orchid Pharma's debt restructuring proposal approved by CDR cell

  The Corporate Debt Restructuring Empowered Group (CDR EG) has approved Orchid Chemicals and Pharmaceuticals' debt restructuring proposal, the pharma company said on Friday.

• Biocon shares surge 11% to new 52-week high

  The shares of Biocon surged today after the biotechnology company entered into an agreement with Quark Pharmaceuticals for development of a new range of therapeutics.

• US regulator raises concerns at Tamil Nadu Hospira facility

  The FDA said it found that surfaces in the facility were not always sanitised prior to use and that sterile drug products were not protected from contamination.

• Orchid Chemicals in talks with lenders to restructure over Rs 1,100 crore loan

  Chennai-based pharma company Orchid Chemicals and Pharmaceuticals is in talks with various lenders to restructure over Rs 1,100 crore loan, which largely comprises working capital loans.

• What is Rakesh Jhunjhunwala buying and selling

  Billionaire investors Rakesh Jhunjhunwala has been restructuring his portfolio amid the broad selloff,.

• Orchid Pharma redeems FCCBs worth $168 mn

  Orchid Pharma is engaged in developing, manufacturing and marketing of diverse bulk actives, formulations and nutraceuticals.

• Defaults on convertible bonds worth $ 1.4bn likely in 2012: Fitch

  As many as 20 per cent of $ 7bn outstanding FCCBs issued are likely to see a default, rating agency FITCH says in a new report.

• Orchid to acquire US-based marketing company Karalex Pharma, LLC

  Front-end marketing arm to add strong generic marketing capability to OrchidOrchid Chemicals & Pharmaceuticals has announced that the company had entered into an agreement to acquire Karalex Pharma, LLC, a US-based generic marketing and sales services company headquartered in New Jersey, USA through an all-cash deal for an undisclosed amount. The t...